glp-1 prescriptions q1 2025 growth Agonists Weight Loss Drugs Market Report, 2025-2030 GLP-1 Antagonists Increase Plan Drug

doi: 10.1085/jgp.200409081

From spring salads to veggie-packed frittatas, enjoy fresh, flavorful meals made with in-season ingredients

In July 2024, Roche, a Swiss-based pharmaceuticals company, acquired Carmot Therapeutics for US$ 2.7 billion (with up to US$ 400 million in additional milestone payments)

Benefits Beyond Weight Loss: Metabolic and Cardiovascular Health Cardiovascular risk reduction semaglutide reduced major cardiovascular events by 20% in the SELECT trial Blood sugar control significant HbA1c reductions in patients with type 2 diabetes or prediabetes Reduced liver fat growing evidence supports GLP-1 therapy for NAFLD and MASLD Sleep apnea improvement tirzepatide demonstrated 63% reduction in apnea-hypopnea index (2024 NEJM trial) Fatty Liver Disease & GLP-1 Therapy Patients with NAFLD/MASLD may see significant improvement with GLP-1 treatment